Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Todos Medical Ltd (OP: TOMDF )

0.0001 UNCHANGED
Last Price Updated: 11:20 AM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Todos Medical Ltd

< Previous 1 2 3 4 5 6 7 Next >
Todos Medical to Present at The LD Micro Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer's Blood Test Clinical Validation Trial vs. Amyloid PET
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Todos Medical Reports Day 26 Update For Case Study #4
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Todos Medical Releases Corporate Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Todos Medical To Present At The Emerging Growth Conference
- Wednesday, April 27, 2022 at 10:00am – 10:45am EST - 
Via Benzinga
Todos Medical Appoints Philippe Goix As Chief Commercial Officer For Provista Diagnostics
Strengthens Management Team and Positions the Company for Growth and Expansion 
Via Benzinga
Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid® by LGC Group
New York, NY, and Tel Aviv, ISRAEL – April 19, 2022 - Todos Medical, Ltd. 
Via Benzinga
UPDATE: Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates
New York, NY, and Tel Aviv, ISRAEL – April 1, 2022 - Todos Medical, Ltd. 
Via Benzinga
Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength including 5 Day Dosing, 30 Day Dosing And 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
5-day and 30-day dosing regimen for 60-pill bottle allows for both support (5-day dosing) to reduce 3CL protease levels and to maintain (30-day dosing) low 3CL protease levels 
Via Benzinga
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Max Strength including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates
New York, NY, and Tel Aviv, ISRAEL – April 1, 2022 - Todos Medical, Ltd. 
Via Benzinga
Todos Medical Reports Case Study Of Patient With Long COVID
New York, NY, and Tel Aviv, ISRAEL, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. 
Via Benzinga
Billy Blanks® Endorses Todos Medical's Line Of Tollovid® Products
New York, NY, and Tel Aviv, ISRAEL – March 27, 2022 - Todos Medical, Ltd. 
Via Benzinga
Todos Medical Initiates IRB-Waived Tollovid® Market Research Study And Announces 50% Price Reduction Until May 30th, 2022
New York, NY, and Tel Aviv, ISRAEL – April 27, 2022 - Todos Medical, Ltd. 
Via Benzinga
Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction until May 30th, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Todos Medical to Present at the Emerging Growth Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Todos Medical Reports 2nd Long COVID Case Study And Launches Website For Physicians And Pediatricians To Indicate Interest In Participating In Tollovid® Long COVID Clinical Study
New York, NY, and Tel Aviv, ISRAEL – April 20, 2022 - Todos Medical, Ltd. 
Via Benzinga
Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
New Study Reportedly Calls Into Question Merck's Ivermectin COVID Off Label Use And May Bolster 3CL Protease Inhibitors Such As Tollovid
Photo credit: Todos Medical This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19 Product Safety
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate Of Free Sale With Daily And Acute Dosing On The Label
New York, NY, and Tel Aviv, ISRAEL – April 6, 2022 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned... 
Via Benzinga
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
New York, NY, and Tel Aviv, ISRAEL – April 4, 2022 - Todos Medical, Ltd. 
Via Benzinga
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
UPDATE: Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Todos Medical Reports Case Study of Patient with Long COVID
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.